Literature DB >> 11678256

Cutaneous T-cell lymphoma in a cardiac transplant recipient.

D M McMullan1, B Radovaneević, C M Jackow, O H Frazier, M Duvic.   

Abstract

Mycosis fungoides, an uncommon form of cutaneous T-cell lymphoma, arises in the skin and frequently progresses to generalized lymphadenopathy Although the cause of cutaneous T-cell lymphoma is unknown, chronic immunosuppression may play a role. A few cases have been reported in renal transplant recipients; however, ours appears to be the 1st report of cutaneous T-cell lymphoma in a cardiac transplant recipient. In our patient, cutaneous manifestations of the disease were noted less than 1 year after transplantation. Seven years after transplantation, Sézary syndrome, a variant form of mycosis fungoides, was diagnosed by tissue biopsy and flow cytometry analysis. Photopheresis improved symptoms but was not well tolerated because of hemodynamic sequelae. Psoralen and ultraviolet A therapy also improved the patient's skin condition, but a generalized lymphadenopathy developed. The maintenance immunosuppressive regimen was changed from cyclosporine (3 mg/kg/day) and azathioprine to cyclosporine (1.5 mg/kg/day) and cyclophosphamide. Although effective in the short-term, the results of this therapeutic strategy could not be fully evaluated because the patient died of acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678256      PMCID: PMC101179     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  23 in total

1.  Brief report: successive occurrence of T-cell and B-cell lymphomas after renal transplantation in a patient with multiple cutaneous squamous-cell carcinomas.

Authors:  S Euvrard; C P Noble; J Kanitakis; M Ffrench; F Berger; H J Delecluse; M D'incan; J Thivolet; J L Touraine
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

2.  Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas.

Authors:  A H Sarris; D Daliani; R Ulmer; M Crow; H E Broxmeyer; W Pugh; M Reiss; F Cabanillas; A B Deisseroth; M Duvic
Journal:  Leuk Lymphoma       Date:  1996-12

3.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

4.  Cutaneous T-cell lymphoma after blood transfusion.

Authors:  D Grossman; M Duvic
Journal:  Lancet       Date:  1993-12-11       Impact factor: 79.321

5.  Cancer in immunosuppressed patients.

Authors:  I Penn
Journal:  Transplant Proc       Date:  1984-04       Impact factor: 1.066

6.  Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion.

Authors:  C M Jackow; J C Cather; V Hearne; A T Asano; J M Musser; M Duvic
Journal:  Blood       Date:  1997-01-01       Impact factor: 22.113

7.  Posttransplant cutaneous lymphoma.

Authors:  J M McGregor; C C Yu; Q L Lu; F E Cotter; D A Levison; D M MacDonald
Journal:  J Am Acad Dermatol       Date:  1993-10       Impact factor: 11.527

8.  Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy.

Authors:  T J Garrett; A Chadburn; M L Barr; R E Drusin; J M Chen; L L Schulman; C R Smith; D S Reison; E A Rose; R E Michler
Journal:  Cancer       Date:  1993-11-01       Impact factor: 6.860

9.  Management of lymphoproliferative disorders after cardiac transplantation.

Authors:  J M Chen; M L Barr; A Chadburn; G Frizzera; F A Schenkel; R R Sciacca; D S Reison; L J Addonizio; E A Rose; D M Knowles
Journal:  Ann Thorac Surg       Date:  1993-09       Impact factor: 4.330

10.  The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients.

Authors:  B A Pancake; D Zucker-Franklin; E E Coutavas
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.